The P-IIb trial evaluating three (25/50/100, qd) & two (25 & 100mg, BID) dosages of JNJ-2113 (IL-23R antagonist peptide) vs PBO in 255 adult patients
The trial achieved all primary & secondary efficacy EPs i.e., patients who received JNJ-2113 achieved PASI 75 (37.2% at 25mg, qd)/(51.2% at 25mg, BID)/(58.1% at 50mg, qd)/(65.1% at 100mg, qd)/(78.6% at 100mg, BID) over 9.3% in PBO, PASI 90 (25.6%/26.8%/51.2%/46.5%/59.5% vs 2.3%) and PASI 100 (11.6%/9.8%/25.6%/23.3%/40.5% vs 0%), respectively, 100% improvement in skin clearance at highest dose level at 16wk.
The therapy was well tolerated, patients experienced one or more AEs was 52.4% vs 51.2%, and no evidence of a dose-dependent increase in the occurrence of specific AEs was reported
Ref: PR Newswire | Image: Janssen
Related Posts:- Janssen Reports P-II Trial (UNITY) Results of Nipocalimab for Pregnant Individuals at High Risk of Early-Onset Severe Hemolytic Disease of the Fetus and Newborn
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
